Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JZP-110 crossover driving study in obstructive sleep apnea with excessive sleepiness
NL-OMON47629Phase 2Active, not recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Jul 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of solriamfetol in obstructive sleep apnea hypopnea syndrome (OSAHS) (2 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Standard deviation of lateral position at 2 hours post-dose. Started Jul 2016; status: active, not recruiting.
02
Drugs
solriamfetol
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on NL-OMON47629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47629.